Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | ACACA | Q13085 | 5/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491754 | 0.90 | ACACA (0.35) | ACACAACACBCNR1CNR2 | |
| SCHEMBL3491751 | 0.90 | ACACA (0.35) | ACACAACACBCNR1CNR2 | |
| SCHEMBL13367509 | 0.88 | ACACA (0.34) | ACACAACACB | |
| SCHEMBL3492929 | 0.86 | ACACB (0.42) | ACACAACACB | |
| SCHEMBL3492926 | 0.86 | ACACB (0.42) | ACACAACACB | |
| SCHEMBL3492942 | 0.82 | HTR2C (0.34) | ACACAACACB | |
| SCHEMBL13340541 | 0.81 | ACACB (0.39) | CRBNACACAACACB | |
| SCHEMBL13340560 | 0.80 | ACACB (0.33) | CRBNACACAACACB | |
| SCHEMBL3494529 | 0.78 | ACACB (0.52) | ACACAACACB | |
| SCHEMBL3494526 | 0.78 | ACACB (0.52) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | CRBN 3767/4885ACACA 1/4885ACACB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.